Achieve Life Sciences nach Reverse Split
Die wenigsten sind sich im Klaren, was ACHV hier überhaupt gerade vorhat. Aber das Timing war nie so ideal für Long ...zum Traden hingegen immer wieder gut gewesen...
Das könnte jetzt plötzlich ganz schnell mit den Amis gehen und nach oben ausbrechen
Unter 2 Dollar eigentlich aktuell ein relativer überschaubarer Kauf
Wir stehen sogar erst noch bei 1.55
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
Charttechnisch erst mal Platz bis 2 USD. Und bei positiven news Urknall?
(ich weis, etwas überschwenglich, aber freu mich eben vorgestern noch mal nachgekauft zu haben und gleich der Anstieg :-)
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
Achieve ist mit Abstand mein bestes Pferd in meinem Depot.
Von meinen 5000 Stück sind noch ganze 10 Stück im Gesamtwert von zur Zeit 2,57 € !! übrig, meinen Einsatz habe ich natürlich in diesem Fall abgehakt.
Anders sieht es m.E. in deinem Fall mit Achieve aus, weiterhin Geduld haben, wenn die Phase 2a und 3 durch sind wird die Aktie auf jeden Fall deinen EK von 3,84 € deutlich überschreiten.
Wie gesagt meine Meinung...
Auf jeden Fall wünsche ich Dir eine Grüne Woche! :-)
https://www.sec.gov/Archives/edgar/data/949858/...8/d717560dsc13g.htm
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
https://www.sec.gov/Archives/edgar/data/949858/...v-sc13ga_123118.htm
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
Topline data from ORCA-1 trial expected in mid-2019
Achieve logo (PRNewsfoto/Achieve Life Sciences, Inc.)
News provided by
Achieve Life Sciences, Inc.
Feb 20, 2019, 05:30 ET
Share this article
SEATTLE and VANCOUVER, British Columbia, Feb. 20, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications.
The Phase 2b trial is evaluating a 25-day treatment course of 1.5 mg or 3.0 mg doses of cytisinicline using either a declining titration schedule or three times daily dosing. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups. The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period, with secondary analyses being conducted on smoking cessation rates, safety, and compliance. Smokers who are participating in the trial receive standardized behavioral support.
ORCA-1 was initiated in October 2018 and enrolled 254 smokers at eight centers across the United States. The trial's Data Safety Monitoring Committee met recently and concluded there are no safety concerns for subjects and the trial should continue as planned. ORCA-1 topline efficacy and safety data are expected to be announced in mid-2019.
"Progress on the cytisinicline development program is rapid and Achieve is grateful to the investigators and study participants for their swift enrollment and commitment to the ORCA-1 trial," said Dr. Cindy Jacobs, Chief Medical Officer at Achieve. "We look forward to sharing the data results in the near future, which will serve to inform our Phase 3 development program."
Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.
About Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, the potential market size for cytisinicline and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
"ORCA is a trademark of Achieve Life Sciences, Inc."
1World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1
SOURCE Achieve Life Sciences, Inc.
Related Links
http://www.achievelifesciences.com
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |
Optionen
| Boardmail an "aktiengirl" |
Wertpapier: Achieve Life Sciences I |